Seviteronel plus chemo for advanced triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests seviteronel together with standard chemotherapy to treat certain types of advanced breast cancer that has spread. It’s looking to see how well the combination works and how safe it is, especially for cancers that are androgen-receptor positive.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to sign consent and follow the visit and treatment schedule.
- Have breast cancer that matches the study type: either hormone-receptor positive or HER2-positive (Part 1), or triple-negative breast cancer that is HER2-negative and androgen-receptor positive (Part 2).
- Have advanced or recurrent breast cancer where docetaxel (a chemotherapy) is a suitable option.
- Have at least one measurable tumor spot that doctors can track on scans.
- Be generally well: performance status 0 or 1, and have blood and organ test results that are adequate within 14 days before the first dose.
- For pregnancy-capable people: agree to effective birth control (or abstinence) during treatment and for a set time after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a PD-L1 antibody (a type of immunotherapy) with a low-dose, continuous chemotherapy regimen called VEX for advanced triple-negative breast cancer that has spread to other parts of the body. It may be an option if you have had only one prior chemotherapy for metastatic disease and have already been treated with certain common chemo drugs.
This Phase 2 trial tests a treatment plan for triple-negative breast cancer that has come back or kept progressing after prior immunotherapy (sometimes along with targeted therapy or chemotherapy). It may help by trying to make the cancer more controllable when it has become resistant to earlier treatment.
This Phase 3 study tests whether a special form of docetaxel (a chemotherapy drug) works better and is safe for people with triple-negative breast cancer that has spread or grown locally. You may be eligible if your cancer is triple-negative and you have measurable disease that can be tracked on scans, along with adequate organ and heart function.
This study tests a new drug called JSKN016 against standard chemotherapy options for triple-negative breast cancer that has stopped responding to previous treatments. The trial aims to find out if JSKN016 works better or offers other benefits for patients like you.
This trial tests atezolizumab (an immunotherapy) plus chemotherapy to activate immune cells in people with triple-negative breast cancer that has spread or cannot be removed. It is for those who have had immunotherapy before during early treatment but not for advanced disease.
This Phase 1/2 study tests a new oral drug (BLEX 404) together with docetaxel to see how safe it is and how well it works for people with advanced or metastatic triple-negative breast cancer. If you qualify, you would receive docetaxel by plan and also take BLEX 404 by mouth each day.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.